- Home
- CCCC vs AGEN Comparison
CCCC vs AGEN Comparison
Compare CCCC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- AGEN
- Stock Information
- Founded
- CCCC 2015
- AGEN 1994
- Country
- CCCC United States
- AGEN United States
- Employees
- CCCC N/A
- AGEN N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCCC Health Care
- AGEN Health Care
- Exchange
- CCCC Nasdaq
- AGEN Nasdaq
- Market Cap
- CCCC 175.1M
- AGEN 142.8M
- IPO Year
- CCCC 2020
- AGEN 2000
- Fundamental
- Price
- CCCC $3.32
- AGEN $4.55
- Analyst Decision
- CCCC Strong Buy
- AGEN Buy
- Analyst Count
- CCCC 4
- AGEN 2
- Target Price
- CCCC $8.50
- AGEN $14.50
- AVG Volume (30 Days)
- CCCC 1.3M
- AGEN 395.5K
- Earning Date
- CCCC 10-30-2025
- AGEN 11-11-2025
- Dividend Yield
- CCCC N/A
- AGEN N/A
- EPS Growth
- CCCC N/A
- AGEN N/A
- EPS
- CCCC N/A
- AGEN N/A
- Revenue
- CCCC $34,240,000.00
- AGEN $101,706,000.00
- Revenue This Year
- CCCC N/A
- AGEN $60.49
- Revenue Next Year
- CCCC N/A
- AGEN N/A
- P/E Ratio
- CCCC N/A
- AGEN N/A
- Revenue Growth
- CCCC 16.55
- AGEN N/A
- 52 Week Low
- CCCC $1.09
- AGEN $1.38
- 52 Week High
- CCCC $7.14
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- CCCC 67.30
- AGEN 48.05
- Support Level
- CCCC $3.21
- AGEN $4.36
- Resistance Level
- CCCC $3.65
- AGEN $5.20
- Average True Range (ATR)
- CCCC 0.25
- AGEN 0.27
- MACD
- CCCC 0.07
- AGEN 0.04
- Stochastic Oscillator
- CCCC 75.00
- AGEN 40.91
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).